The Gene Box
Calibrate

Clopidogrel and CYP2C19: what the genotype tells the prescriber

Why genotype matters for clopidogrel

Clopidogrel is a prodrug. To have an antiplatelet effect it has to be converted to its active metabolite, and that conversion is carried out mainly by the liver enzyme CYP2C19.

Patients with one or two no-function (loss-of-function) CYP2C19 alleles, such as *2 and *3, make less active metabolite. CPIC classes them as intermediate or poor metabolisers. They get less platelet inhibition from standard-dose clopidogrel. CPIC's 2022 guideline reports a higher risk of major adverse cardiovascular and cerebrovascular events in these patients.

CPIC defines eight CYP2C19 phenotypes: ultrarapid, rapid, normal, likely intermediate, intermediate, likely poor, poor, or indeterminate.

Published guidance (background)

  • FDA labelling (Plavix): the boxed warning covers diminished antiplatelet effect in patients with two loss-of-function CYP2C19 alleles ("CYP2C19 poor metabolizers"). It notes that tests are available to identify these patients and advises considering another platelet P2Y12 inhibitor in patients identified as poor metabolisers.
  • FDA Table of Pharmacogenetic Associations: for CYP2C19 intermediate or poor metabolisers, it lists lower active-metabolite concentrations and lower antiplatelet response, possibly with higher cardiovascular risk, and says "Consider use of another platelet P2Y12 inhibitor."
  • CPIC guideline (2022 update): expands the indications for CYP2C19 genotype-guided antiplatelet therapy compared with 2013, strengthens the recommendation for intermediate metabolisers, and updates how genotype translates to phenotype. For patients with acute coronary syndrome and/or undergoing PCI, CPIC (2022) recommends avoiding standard-dose clopidogrel in intermediate metabolisers, and avoiding clopidogrel in poor metabolisers, if possible, using prasugrel or ticagrelor at standard dose if there is no contraindication (strong recommendation). Recommendations for other cardiovascular and neurovascular indications differ by phenotype; see the guideline's Tables 2 and 3.

Limits

  • Genotype is one input. Clinical indication, bleeding risk, interacting drugs and patient factors also matter.
  • A result of "no variant detected" applies only to the alleles tested.
  • This is decision-support. The prescribing doctor decides on therapy.

How to order

Order Calibrate on its own. CYP2C19 is reported along with the other genes tested. → /for-doctors#order-calibrate

Drug-gene guides

FAQ

Should I test CYP2C19 before prescribing clopidogrel?
The FDA label notes that tests are available to identify CYP2C19 poor metabolisers. CPIC gives genotype-guided recommendations for patients whose genotype is known. Whether to test is the prescribing doctor's decision.
What does a CYP2C19 poor metaboliser result mean for clopidogrel?
The patient has two loss-of-function alleles and makes less of clopidogrel's active metabolite. The FDA label advises considering another platelet P2Y12 inhibitor for these patients.
What about intermediate metabolisers?
They typically carry one normal- or increased-function allele and one no-function allele (for example *1/*2 or *2/*17). The 2022 CPIC update strengthened the recommendation for this group. The FDA Table of Pharmacogenetic Associations covers both intermediate and poor metabolisers.
Where can a doctor in India order CYP2C19 testing?
CYP2C19 is included in Calibrate, The Gene Box PGx test. A doctor can order it on its own through /for-doctors.

Sources (verified 27 Oct 2026)